Tenidap, a structurally novel drug for the treatment of arthritis: Antiinflammatory and analgesic properties

Inflammation Research

Volumn 45, Issue 2, 1996, Pages 54-61

  Moore, P F ^a   Larson, D L ^a   Otterness, I G ^a   Weissman, A ^a   Kadin, S B ^a   Sweeney, F J ^a   Eskra, J D ^a   Nagahisa, A ^a   Sakakibara, M ^a   Carty, T J ^a  

^a PFIZER INC   (United States)

Author keywords

Analgesia; Antiinflammatory; Cycleoxygenase 1; Cyclooxygenase 2; Tenidap

Indexed keywords

ACETIC ACID; ANTIRHEUMATIC AGENT; CARRAGEENAN; IBUPROFEN; INDOMETACIN; NAPROXEN; PHENYLQUINONE; PIROXICAM; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE; TENIDAP;

ADRENAL GLAND; ADRENALECTOMY; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; MALE; MAST CELL LEUKEMIA; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; POLYARTHRITIS; PROSTAGLANDIN SYNTHESIS; RAT;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ARTHRITIS; CYCLOOXYGENASE INHIBITORS; DOGS; GUINEA PIGS; HAPLORHINI; HUMANS; INDOLES; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 9044253709     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02265116     Document Type: Article

References (60)

1. Kalz P, Borger AP, Loose LD. Evaluation of CP-66,248 [5-chloro-2,3-dihydro-2-thienylcarbonyl)-indole-1-carboxamide] in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 1988; 31(Suppl 4):52.
2. Davis JS, Loose LD, Borger AP. Clinical efficacy of CP-66,248 [5-chloro-2,3-dihydro-2-thienylcarbonyl)-indole-1-carboxamide] in osteoarthritis (OA) [abstract]. Arth Rheum 1988;31(Suppl 4):72.
3. Loose LD, Sipe JD, Kirby DS, Kraska AR, Weiner ES, Shanahan WR, et al. Reduction in acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drue. Br J Rheumalol 1993;32 Suppl 3:19-25.
4. Genant HK, Kirby DS, Pickering EA, Loose LD, Weiner ES, Kraska AR, et al. Tenidap slows X-ray progression in rheumatoid arthritis [abstract]. Rheumatol Eur 1995;24:224.
5. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Sem Arthr Rheum 1994;24:91-104.
6. Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Brit J Rheumatol 1986;25:44-9.
7. McConkey B, Crockson RA, Crockson AP, Wilkinson AR. The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis. Quart J Med 1973;42:785-91.
8. Larsen A. The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:123-9.
9. Conklyn MR, Kadin SB, Showell HJ. Inhibition of IgE-mediated N-acetylglucosaminidase and serotonin release from rat basophilic leukemia cells (RBL-2H3) by tenidap, a novel antiinflammatory agent. Int Arch Allergy Appl Immunol 1990;92:369-73.
10. Otterness IG, Golden HW, Kadin SB. CP-66,248, a novel antiarthritic agent that inhibits in vivo basophil degranulation [abstract]. Arthr Rheum 1989;32 Suppl 4:146.
11. Blackburn WD, Jr, Heck LW, Loose LD, Eskra JD, Carty TJ. Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arth Rheum 1991;34:204-10.
12. Blackburn WD, Jr, Loose LD, Heck LW, Chatham WW. Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase. Arth Rheum 1991;34:211-6.
13. Littman B, Drury C, Zimmerer R, Stack C, Law C. Rheumatoid arthritis treated with tenidap and piroxicam: Clinical associations with cytokine modulation by tenidap. Arth Rheum 1995;38:29-37.
14. Otterness IG, Bliven ML, Downs JT, Natoli EJ, Hanson DC. Inhibition of interleukin 1 synthesis by tenidap: A new drug for arthritis. Cytokine 1991;3:227-83.
15. Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. J Immunol 1992;148:480-4.
16. Pelletier JP, McCollum R, DiBattista J, Loose LD, Cloutier JM, Martel-Pelletier J. Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arth Rheum 1993;36:1517-27.
17. Laliberte R, Perregaux D, Svensson L, Pazoles CJ, Gabel CA. Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL-1β production from ATP-treated monocytes and macrophages. J Immunol 1994;153: 2168-79.
18. Fernandes J, Martel-Pelletier J, Otterness I, Lopez-Anaya A, Mineau F, Tardif G, et al. Effects of tenidap on canine experimental osteoarthritis: 1. Morphological analysis and metalloproteinase activity. Arthr Rheum 1995;38:1290-301.
19. Wylie G, Appelboom T, Bolten W, Breedveld F, Feely J, Leeming R, et al. A 24-week comparative study of tenidap, a cytokine-modulating antirheumatic drug, and diclofenac in rheumatoid arthritis. Brit J Rheumatol 1995;34:554-63.
20. Blackburn WD, Jr, Prupas HM, Silverfield JC, Poiley JE, Caldwell JR, Collins RL, et al. Tenidap in rheumatoid arthritis: a 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arth Rheum 1995;38:1447-56.
21. Dawson W, Willoughby DA. Inflammation - mechanisms and mediators. In: Lombardino JG, editor. Nonsteroidal antiinflammatory drugs. New York, NY: John Wiley & Sons, 1985: 77-109.
22. Masterrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9.
23. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266: 23261-7.
24. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
25. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267:4338-44.
26. Jones DA, Carlton DP, McIntyre T, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-54.
27. Reddy RT, Hershman HR. Ligand-induced prostaglandin synthesis requires expression of TIS10/PGS2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 1994;269:15473-80.
28. Kadin SB, inventor. US patent 4,556,672. 1985.
29. Carty TJ, Marfat A, Moore PF, Falkner FC, Twomey TM, Weissman A. Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Agents Actions 1993;39:157-65.
30. Sweeney FJ, Eskra JD, Carty TJ. The use of 12-hydroxypeptadecatrienoic acid (HHT) as an HPLC/spectrophotometric marker for cyclooxygenase pathway activity in resident rat peritoneal cells. Prost Leuk Med 1987;28:171-7.
31. Winter CA, Risley EA, Nuss GW. Carrageenan-induced edema in the hind paw of the rat as an assay for antiinflammatory activity. Proc Soc Exp Biol Med 1962;111:544-7.
32. Lombardino JG, Otterness IG, Wiseman EH. Acidic antiinflammatory agents - correlations of some physical, pharmacological and clinical data. Arzneim Forsch 1975;25:261-92.
33. Winder CV, Wax J, Burr V, Been M, Rosiere CE. A study of pharmacologic influences on ultraviolet erythema in guinea pigs. Arch Int Pharmacodyn 1962;116:261-92.
34. Otterness IG, Wiseman EH, Gans DJ. A comparison of the carrageenan edema test and the ultraviolet light-induced erythema test as predictors of the clinical dose in rheumatoid arthritis. Agents Actions 1979;9:177-83.
35. Walz DT, DiMartino MJ, Kuch JH, Zuccarello W. Adjuvant-induced arthritis in rats. i. Temporal relationship of physiological, biochemical, and hematological parameters. Proc Soc Exp Biol Med 1971;136:907-10.
36. Larson DL, Lombardino JG. The topical antiinflammatory effects of piroxicam in rodents. Agents Actions 1980;10:246-51.
37. Siegmund E, Cadmus R, Lu G. A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med 1957;95:729-31.
38. Milne GM, Twomey TM. The analgetic properties of piroxicam in animals and correlation with experimentally determined plasma levels. Agents Actions 1980;10:31-7.
39. Niemegeers CJE, van Bruggen JAA, Janssen PAJ. Suprofen, a potent antagonist of acetic acid writhing in rats. Arzneim Forsch 1975;25:1505-9.
40. Levine L. Inhibition of the A-23187-stimulated leukotriene and prostaglandin biosynthesis of rat basophil leukemia (RBL-1) cells by nonsteroidal anti-inflammatory drugs, antioxidants, and calcium channel blockers. Biochem Pharmacol 1983;32:3023-6.
41. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs. Drug Devel Res 1992;25:249-65.
42. Laneuville N, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal antiinflammatory drugs. J Pharm Exp Therap 1994;271:927-34.
43. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthetase: cDNA cloning, expression, and gene chromosomal assignment. FASEB 1991;5:2304-11.
44. Habib A, Créminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 1993;266:23448-54.
45. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994;1209-1309.
46. Woodward DF, Raval P, Pipkin MA, Owen DA. Re-evaluation of the effect of nonsteroidal antiinflammatory agents on U.V. induced cutaneous inflammation. Agents Actions 1981;11:711-7.
47. Davies P, Bailey PJ, Goldenberg MM. The role of arachidonic acid oxygenation products in pain and inflammation. Ann Rev Immunol 1984;2:335-57.
48. Needleman PJ, Turk BA, Jakschik AR, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1990;55:69-102.
49. Carty TJ, Marfat A, Masamune H. Modulation of arachidonic acid metabolism in the treatment of rheumatoid arthritis. Ann Rep Med Chem 1988;23:181-9.
50. 4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1988;1:35-9.
51. Proudman KE, MacMillan R. Are tolfenamic acid and tenidap dual inhibitors of 5-lipoxygenase and cyclo-oxygenase? Agents Actions 1991;34:121-4.
52. Knott I, Dieu M, Burton M, Houbion A, Remacle J, Raes M. Induction of cyclooxygenase by interleukin 1: comparative study between human synovial cells and chrondrocytes. J Rheumatol 1994;21:462-6.
53. O'Neill LAJ, Lewis GP. Induction of cyclo-oxygenase by IL-1 in rheumatoid synovial cells. FEBS Lett 1987;212:35-9.
54. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
55. Kennedy BP, Chan C-C, Culp S, Cromish W. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 1993;197:494-500.
56. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-50.
57. Otterness IG, Gans DJ. Nonsteroidal antiinflammatory drugs: An analysis of the relationship between laboratory animal and clinical doses, including species scaling. J Pharmaceut Sci 1988; 77:790-5.
58. Otterness IG, Bliven ML. Laboratory models for testing nonsteroidal antiiflammatory drugs. In: Lombardino JG, editor. Nonsteroidal antiinflammatory drugs. New York, NY: John Wiley & Sons, 1985:111-252.
59. Sunshine A, Olson NZ, Zighelboim I, DeCastro A. Analgesic efficacy of tenidap versus naproxen for the treatment of post episiotomy pain [abstract]. Clin Pharm Therap 1994;55:128.
60. Fricke JR, Loose LD, Fite F. Tenidap (T), naproxen (N), or placebo (P) in post dental surgery pain [abstract]. Clin Pharm Therap 1994;55:127.